Chapter 32 — Key Takeaways

How Peptides Are Made — Solid-Phase Synthesis, Recombinant Production, and Why Peptide Drugs Cost What They Cost

The one thing

At 99% coupling efficiency per step, a 30-residue peptide comes out of the reactor about 74% correct — and the other 26% is not nothing. It is deletion sequences: chains missing one residue out of thirty, nearly indistinguishable from the product by every property a chromatograph measures.

Everything else in this chapter is downstream of that sentence.

§32.1 — Merrifield's idea

• Solid-phase peptide synthesis (SPPS), published 1963; Nobel Prize in Chemistry 1984.
• The insight: anchor the growing chain to an insoluble solid support so that excess reagents and byproducts can be washed away at every step, rather than purifying after every coupling.
• This converted the between-steps purification from a research problem into a filtration step — and anything a valve can do, a machine can do. Automated synthesizers followed within a decade.
• Essentially every compound in this book exists because of it — the approved drugs and the gray-market vials alike. Low barriers cut both ways.

§32.2 — The Fmoc cycle

• Each cycle: deprotect the N-terminal cap → wash → couple the next protected amino acid using an activating reagent → wash. Repeat per residue. Then cleave from the resin and remove side-chain protecting groups.
• Side chains carry their own protecting groups so that only the intended bond forms. The whole art is controlling which reaction happens where.
• The two protecting-group levels must respond to different triggers — Fmoc comes off with base every cycle; side chains and linker come off with acid, once, at the end.
• Chains are built C-terminus toward N-terminus, the reverse of a ribosome. The final molecule is identical.
• Racemization during activation gives a mirror-image residue at nearly identical mass.
• Difficult sequences aggregate on the resin, burying the reactive site. Per-step efficiency is not uniform across a sequence.

§32.3 — The arithmetic (the chapter's spine)

• After n couplings at efficiency e, the fraction of correct full-length chains is eⁿ.
• 10 residues ≈ 90% · 30 residues ≈ 74% · 50 residues ≈ 61% at 99% per step.
• At 98% per step, 50 residues gives roughly 36%. One percentage point nearly doubles the yield over fifty steps.
• The remainder is deletion sequences — chains that missed a coupling and then accepted the next residue, leaving an internal gap.
• A 29-residue impurity in a 30-residue product has nearly identical charge, hydrophobicity, and retention time. Very hard to separate and easy to miss. This is the link to Chapter 34 and to Chapter 19.
• Capping converts deletion sequences into truncated ones, which separate easily. It does not improve yield; it buys separability.
• Semaglutide's position-34 substitution (Chapter 4 §4.5) exists to give exactly one lysine for fatty-acid attachment, eliminating a mixture of attachment isomers — identical mass, identical composition, different attachment point, and nearly impossible to separate. A residue changed for a manufacturing reason.

§32.4 — Purity, and what it leaves out

• Preparative HPLC is the workhorse. Every purification trades purity against recovery, and always discards material.
• "98% pure" is a statement about a specific analytical method's output. The questions are pure by what measure and with respect to what.
• Purity by peak area does not establish identity, does not quantify a co-eluting impurity, and says nothing about water, counterion, residual solvent, or endotoxin.
• A vial that is 98% pure peptide by HPLC may still contain a substantial mass fraction that is not peptide at all — trifluoroacetate counterion and water being the usual examples.
• Peptide purity and peptide content are different numbers, determined by different methods.
• Sterility, endotoxin, particulates, and stability are separate questions that no chromatogram addresses.

§32.5 — Recombinant production

• Insert a gene into a host (commonly E. coli or yeast), grow at scale, harvest the product.
• Human insulin, 1982, was the first approved recombinant drug (Chapter 11).
• Why insulin was hard: folding, not expression. Two chains joined by disulfide bonds; six cysteines can pair fifteen ways and only one is insulin.
• Early strategy: express the chains separately and combine them. Later strategy: express proinsulin — a single chain whose connecting segment makes folding easy — then cleave it enzymatically.
• In recombinant production, expression is often the easy half and folding the hard half.

§32.6 — Choosing between the routes

• Synthesis suits shorter peptides, permits non-natural amino acids, and permits site-specific chemical modification like lipidation.
• Recombinant suits longer chains, is cheaper per gram at scale, and handles complex folding.
• Semaglutide's Aib at position 8 cannot be made ribosomally — no codon encodes it — so semaglutide requires chemical steps regardless of anything else.
• Growth hormone at 191 residues is recombinant; a 9-residue peptide is synthetic; semaglutide sits in between and uses both kinds of step.
• Many modern products are hybrids — recombinant or synthetic backbone plus defined chemical modification. The routes are stages, not rivals.

§32.7 — The shortage constraint

• The binding limitation on GLP-1 supply was not peptide synthesis.
• It was aseptic fill-finish capacity and injector-pen assembly — the final steps, requiring large sterile facilities and precision device manufacturing, both heavily regulated.
• A sterile fill line takes years to build and qualify. Peptide injectables cannot be terminally sterilized, so filling must be aseptic.
• This is why the shortage persisted despite enormous commercial incentive, and why nobody could solve it quickly. You cannot buy your way out of a constraint whose limiting factor is time.
• Remember this whenever a drug shortage is explained in terms of the active ingredient.

§32.8 — The honest cost stack

Synthesis or fermentation · purification · formulation · aseptic fill-finish · delivery device · cold chain · quality control (identity, purity, potency, sterility, endotoxin) · plus recovered development cost including failed programs · plus market structure.

• The first block is genuinely substantial. "Pennies to make" is not accurate for a finished, sterile, tested, device-delivered product.
• And the first block does not explain the price. The same product, same manufacturer, same facility, sells at radically different prices in different countries. No cost-of-goods account explains that.
• Chapters 11 and 12 covered the rest: exclusivity, market structure, payer negotiation, and recovery of development cost including failed programs.

§32.9 — The payoff

A gray-market vial's price reflects synthesis and basic purification and essentially nothing else — no sterile fill-finish, no formulation science, no QC system, no device, no cold-chain guarantee, no regulatory compliance, no clinical evidence, and no liability.

It is cheaper because it is a different product, not because someone found efficiencies.

• This is not a claim that prescription pricing is justified. Chapter 12 remains critical of it.
• It is a claim about what a price difference is evidence of: largely a measure of what has been removed.
• A price gap is not evidence that the molecule is easy to make.
• A certificate of analysis does not close the gap — it addresses two items on a long list.

Ratings issued in this chapter

Note that none of these rate a molecule. They rate claims about products and processes — which is what rule 1 of the rating system requires, and a useful reminder that the system is about claims, not compounds.

Dossier progress

Field 1 revisited. Two vials labeled identically may differ in impurity profile, deletion-sequence content, counterion, water content, actual peptide mass, sterility status, and storage history. For each dossier compound, record what you would need to know to say two preparations are "the same." Date the entry — manufacturing changes.

Carry forward

• Chapter 33 takes up the other half of Part VI: how peptides are designed. You have already met several of its tools here — the Aib substitution, the lipidation handle, the arginine at position 34.
• Chapter 34 is the analytical counterpart to §32.3 and §32.4: what testing can and cannot establish about a preparation.
• Chapters 11 and 12 are where the cost stack's last two blocks live. This chapter deliberately does not relitigate them.